Contact

Track record : past and current projects

CELL THERAPY 

Pre-clinical assessment of pluripotent stem cell therapy for Huntington’s disease

COORDINATION

A. Perrier (BIRD)

PARTNERS

P. Hantraye (CEA), David Sourdive (Cellectis)

FOUNDING

ANR RFSC 2011-2014 & NeuroStemCell FP7 project
 

REPAIR-HD : Human pluripotent stem cell differenciation, safety and preparation for therapeutic transplantation in Huntington's disease

COORDINATION

A. Rosser

PARTNERS

A.Perrier (BIRD), P. Hantraye (CEA), A. Bachoud-Levi (UPEC)

FOUNDING

Repair-HD FP7 project (En cours)

Muticentric intra-cerebral grafting in Huntington’s disease

COORDINATION

AC Bachoud-Lévi (UPEC)

PARTNERS

S. Palfi (APHP), P. Remy (UPEC), P. Maison, P. Hantraye (CEA), M. Peschanski (BIRD)

FOUNDING

DRCD AP-HP, PHRC 2000, 2004, 2011 (2001–2014)

Hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy

COORDINATION

P. Aubourg and N. Cartier (Inserm)

PARTNERS

M. Cavazzana-Calvo, S Hacein-Bey-Abina, A. Fischer (Necker-Enfants Malades, Paris), C. van Kalle, M. Schmidt, A (DKFZ, Heidelberg)

FOUNDING

Inserm, AP-HP, University Paris-Descartes, ELA, AFM, Bluebirdbio (2006 – ongoing)

Hematopoietic stem cell gene therapy with lentiviral vector in RETT syndrome

COORDINATION

N. Cartier, P Aubourg (Inserm)

PARTNERS

Eithan Galun (Goldyne Savad Institute of Gene Therapy, Hadassah, Israel)

FOUNDING

Inserm, AFM

 

 

GENE THERAPY 

A phase I/II, Open Labeled, Monocentric gene therapy Study in Children with Metachromatic Leukodystrophy

COORDINATION

P. Aubourg (Inserm)

PARTNERS

R. Crystal (Cornell University, USA), Ph.Moullier, L.Hertz-Panier (CEA)

FOUNDING

ELA foundation, AP-HP, University Paris Descartes, Inserm (2012– 2016)

Brain gene therapy with AAVrh10 encoding human CYP46A1 in inherited forms of Alzheimer and Tauopathie

COORDINATION

Nathalie Cartier

PARTNERS

L. Buée (Inserm U837), O. Laprevote (Fac. Paris-Descartes), B. Delatour, Ch. Duyckaerts, Ph. Hantraye

FOUNDING

ANR-Canada, France Alzheimer, Fondation Del Ducca (2010 – 2014)

Targeting therapeutic genes to oligodendrocytes in brain and spinal cord

COORDINATION

C. Sevin, P. Aubourg (Inserm)

PARTNERS

M-A Colle (Inserm/INRA)

FOUNDING

Fondation Del Ducca (2011 – 2013)

Gene therapy for Huntington’s disease using LV-CNTF

COORDINATION

G. Bonvento (CEA), AC Bachoud-Lévi (UPEC)

PARTNERS

P. Hantraye (CEA), P. Remy (UPEC) and S. Palfi (APHP)

FOUNDING

APHP, DRCD 2000 and now submitted to the AFM (2011–2014)

Optimization of intrathecal delivery of various AAV vectors

COORDINATION

M-A. Colle (INRA)

PARTNERS

P. Aubourg (Inserm)

FOUNDING

AFM (under evaluation)

PROSAVIN Dopamine gene based treatment for Parkinson's disease

COORDINATION S.Palfi (APHP)
PARTENAIRES CEA/ APHP/ UPEC
FOUNDING Oxford Biomedica (2003-2023)

DopaGen

COORDINATION S.Palfi (APHP)
PARTNERS Ph. Hantraye (CEA)
FOUNDING ANR (2014-2017)




 

MODELS and BIOMARKERS

Assessing neurodegeneration, intracellular viscosity and molecular crowding in vivo using diffusion-weighted and proton/phosphorus NMR spectroscopy

COORDINATION

J. Valette

PARTNERS

 

FOUNDING

Eli Lilly (2009)

Development & characterization of a primate model of periventricular leucomalasia

COORDINATION

F. La Chapelle (Inserm)

PARTNERS

P. Gressens (Inserm), L. Hertz-Pannier (CEA)

FOUNDING

INSERM-CEA (2009-2015)

Imaging CNS demyelination and remyelination in Multiple Sclerosis using PET

COORDINATION

Bruno Stankoff (IHU-A-ICM)

PARTNERS

M. Bottlaender (CEA)

FOUNDING

ELA, INSERM-DHOS, FRM, JNLF (2009-2012)

Microglial activation in Parkinson’s Disease

COORDINATION

P. Rémy (UPEC)

PARTNERS

P. Rémy P. Hantraye (CEA), M. Vidailhet & A. Brice (IHU)

FOUNDING

France-Parkinson (2011–2013)

HDeNERGY : Validation of molecular neuroimaging biomarkers in Huntington's disease in view of therapeutic trials targeting the Krebs cycle

COORDINATION

E. Brouillet (CEA)

PARTNERS

F. Mochel (IHU-A-ICM)

FOUNDING

ANR (2015-2018)

PRIMA-TAU. A primate model of tauopathies

COORDINATION

P.Hantraye (CEA)

PARTNERS

Luc Buee (Inserm, Lille)

FOUNDING

Fondation Plan Alzheimer (2011-2013)

A primate model of Huntington’s disease and the assessment of Si-RNA therapy

COORDINATION

N. Deglon (CHUV, Lausanne, Switzerland)

PARTNERS

I2BM ET UPEC

FOUNDING

CEA/CHUV

ASTROinAD : Towards a gene therapy targeting astrocytes in AD

COORDINATION G. Bonvento (CEA)
PARTNERS Bruno Cauli (IHU-A-ICM), Stéphane Oliet (Inserm U682)
FOUNDING Association France Alzheimer- Fondation de France

LRRK2 : Etude de la neurotoxicité des domaines fonctionnels de LRRK2 par vectorisation virale : vers de nouveaux modèles génétiques chez le rat et le primate non humain

COORDINATION

E. Brouillet (CEA)
PARTNERS  
FOUNDING Fondation de France (2011-2013)

LRRK2 and alpha-synucléine : Fonctionnal interaction between LRRK2 and in vivo alpha-synucléine

COORDINATION E. Brouillet (CEA)
PARTNERS  
FOUNDING Fondation de France (2012-2016)

Inductibility of amyloidosis and Tau pathologies in Alzheimer's disease : Feasability ans mechanisms of action in a non human primate model

COORDINATION M. Dhenain (CEA)
PARTNERS F. Pifferi, UMR 8571 Brunoy
FOUNDING France-Alzheimer (2012-2015)

New tools for the diagnosis of Alzheimer's disease : LLAMA VHH antibody fragments targeting amyloid plaques and neurofibrillary lesions (LLAMALZ)

COORDINATION P. Lafaye (Institut Pasteur)
PARTNERS M. Dhenain (CEA), B. Delatour (IHU), S; Bay (Institut Pasteur)
FOUNDING Institut Roche de Rechecrhe et Médecine Translationnelle (2011-2014)

 

DRUG BASED THERAPIES

Nucleipark

COORDINATION

M. Vidailhet (IHU) & C. Poupon (CEA)

PARTNERS

CEA, APHP, INSERM, INRIA

FOUNDING

ANR, ENP, France Parkinson, APHP, INSERM

LRRK2 prospective cohort: identifying pre-symptomatic markers in Parkinson’s

COORDINATION

A Brice (IHU)

PARTNERS

P. Remy (UPEC), P. Hantraye (CEA), MJFF, AP-HP

FOUNDING

APHP – INSERM - MJFF (2009-2014)- Fondation Avenir

Study of S47445 in a rat model of Huntington's disease

COORDINATION

E. Brouillet (CEA)

PARTNERS

 

FOUNDING

Servier (2012-2014)

SCREENTOX:Stem Cells for Replicable Efficient Extended and Normalized Toxicology

COORDINATION

M. Peschanski

PARTNERS

European Network (13 partners in 5 countries)

FOUNDING

EC (2011-2015)

Study of S47445 in a primate model of Huntington's disease

COORDINATION

R. Aron Badin (CEA)

PARTNERS

 

FOUNDING

Servier (2012-2013)



 

PEDIATRY

The blood brain barrier in perinatal brain damage

COORDINATION

P. Gressens

PARTNERS

Inserm

FOUNDING

FP7 (2010 – 2013), Leducq Foundation (2010-2014)

Rare infantile epilepsies: use of clinical trial simulation for the choice and optimization of study design

COORDINATION

C. Chiron

PARTNERS

Gerard PONS, Vincent JULLIEN (U663)

FOUNDING

ERA-NET PRIOMEDCHILD (2011 – 2013), INSERM & APHP (2011 – 2012)

In vitro study of the human blood brain barrier at pediatric age

COORDINATION

C. Chiron

PARTNERS

G. PONS (U663)

FOUNDING

ANR (01/2010 – 12/2012)

Impact du stress foetal sur la santé mentale : les facteurs HSF (Heat Shck Fcators), médiateurs d'événements épigénétiques

COORDINATION V. Mezger (CNRS)
PARTNERS P. Gressens (Inserm UMR1141), J. Gallego (Inserm UMR1141)
FOUNDING ANR Samenta (2014-2016)

Validate an immunoassay based on electro-chemo-luminescence to measure cytokine levels in human plasma in indviduals with psychiatric disorders

COORDINATION N. Glaichenhaus (Universite de Nice Sophia Antipolis)
PARTNERS P. Gressens (Inserm UMR1141), R. Belzaux (APHM), M. Leboyer (Inserm UMR955)
FOUNDING Projet incitatif immuno-psychiatrie ITMO IHP (2014)

Role of microglial metabolism in perinatal inflammation

COORDINATION P. Gressens (Inserm UMR1141)
PARTNERS P. Carmeliet (KUL, Leuven, Belgique), C. Verderio(CNR, Milan, Italie), H. Hagberg (University of Göteborg, Suède)
FOUNDING ERA-NET Neuron (2015-2017)

Rôle de l'inflammation périnatale dans la physiopathologie des troubles du spectre autistique

COORDINATION P. Gressens (Inserm UMR1141)
PARTNERS R. Delorme (APHP)
FOUNDING Fondation de France (2015-2016)